Advances in tissue kallikrein for acute ischemic stroke
10.3969/j.issn.1002-0152.2025.02.009
- VernacularTitle:组织激肽释放酶治疗急性缺血性卒中的研究进展
- Author:
Jian ZHANG
1
;
Jinsheng ZENG
1
Author Information
1. 中山大学附属第一医院神经科,广东省重大神经疾病诊治研究重点实验室,国家临床重点专科和国家重点学科(广州 510080)
- Publication Type:Journal Article
- Keywords:
Acute ischemic stroke;
Tissue kallikrein;
Human urinary kallidinogenase;
Ischemic penumbra;
Bio-marker;
Neurological function improvement;
Cardio-cerebrovascular protection
- From:
Chinese Journal of Nervous and Mental Diseases
2025;51(2):115-120
- CountryChina
- Language:Chinese
-
Abstract:
Acute ischemic stroke(AIS)is a common neurological disorder that still presents many challenges despite advancements in diagnostic and therapeutic techniques.Tissue kallikrein(TK),a cardiovascular and cerebrovascular protective factor,is involved in the entire process of AIS and holds significant clinical value.This review explores the mechanisms of TK in AIS,including targeting collateral circulation improvement in ischemic areas,protecting neurovascular coupling,reducing neuronal injury,and participating in remote ischemic conditioning.Additionally,plasma TK levels are negatively correlated with AIS incidence and recurrence risk,which can serve as a potential biomarker.TK therapy has been shown to improve neurological function in AIS patients,reduce recurrence rates and enhance outcomes when combined with reperfusion therapies.TK also demonstrates therapeutic benefits in AIS patients with multiple organ comorbidities.This review concludes the important roles of TK in the diagnosis,treatment,and prevention of AIS,providing new insights for future research and clinical applications.
